n-n-dimethylglycylamidominocycline and Gram-Positive-Bacterial-Infections

n-n-dimethylglycylamidominocycline has been researched along with Gram-Positive-Bacterial-Infections* in 2 studies

Other Studies

2 other study(ies) available for n-n-dimethylglycylamidominocycline and Gram-Positive-Bacterial-Infections

Article	Year
In-vitro activity of two glycylcyclines against enterococci resistant to other agents. The Journal of antimicrobial chemotherapy, 1995, Volume: 35, Issue:6 Two new glycylcyclines, CL 329,998 and CL 331,002, were tested for in-vitro activity against 178 clinical strains of enterococci which were resistant to one or more of the commonly used agents (ampicillin, high level gentamicin, vancomycin and teicoplanin). Both glycylcyclines demonstrated good activity (MICs < or = 0.5 mg/L) against all isolates tested, including those strains which demonstrated multiple resistance. As resistant enterococci are increasing in importance, new agents with activity against these strains are urgently required. Glycylcyclines have in-vitro activity which suggests they may be useful agents for treatment of infections caused by these organisms. Topics: Anti-Bacterial Agents; Drug Resistance, Multiple; Enterococcus; Gram-Positive Bacterial Infections; Humans; Microbial Sensitivity Tests; Minocycline; Phenotype; Tetracyclines	1995
In vitro activities of two glycylcyclines against gram-positive bacteria. Antimicrobial agents and chemotherapy, 1994, Volume: 38, Issue:3 The glycylcyclines designated CL 329,998 and CL 331,002 are N,N-dimethylglycylamido derivatives of minocycline and 6-demethyl-6-deoxytetracycline, respectively. In vitro activities of these two antimicrobial agents were compared with those of tetracycline, minocycline, and seven other antimicrobial agents against 412 gram-positive organisms. Both new drugs were significantly more active than minocycline against methicillin-resistant Staphylococcus aureus (MICs for 90% of isolates tested, 0.25 and 0.5 microgram/ml versus 4 micrograms/ml). CL 329,998 inhibited all streptococci, lactobacilli, and Leuconostoc spp. at concentrations of < or = 0.5 microgram/ml, with CL 331,002 slightly less active against some species. All enterococci, including minocycline-resistant and multidrug-resistant isolates, were inhibited at < or = 0.5- and < or = 1.0-microgram/ml concentrations of the new drugs, respectively. Only bacteriostatic activity was evident by time-kill curves. The two glycylcyclines demonstrated activities in vitro that were superior to those of minocycline against several gram-positive bacterial species, and at relatively low concentrations, they inhibited isolates resistant to both tetracycline and minocycline. Topics: Anti-Bacterial Agents; Drug Resistance, Microbial; Gram-Positive Bacteria; Gram-Positive Bacterial Infections; Humans; Microbial Sensitivity Tests; Minocycline; Tetracyclines; Time Factors	1994

Article

Year

In-vitro activity of two glycylcyclines against enterococci resistant to other agents.

The Journal of antimicrobial chemotherapy, 1995, Volume: 35, Issue:6

Two new glycylcyclines, CL 329,998 and CL 331,002, were tested for in-vitro activity against 178 clinical strains of enterococci which were resistant to one or more of the commonly used agents (ampicillin, high level gentamicin, vancomycin and teicoplanin). Both glycylcyclines demonstrated good activity (MICs < or = 0.5 mg/L) against all isolates tested, including those strains which demonstrated multiple resistance. As resistant enterococci are increasing in importance, new agents with activity against these strains are urgently required. Glycylcyclines have in-vitro activity which suggests they may be useful agents for treatment of infections caused by these organisms.

Topics: Anti-Bacterial Agents; Drug Resistance, Multiple; Enterococcus; Gram-Positive Bacterial Infections; Humans; Microbial Sensitivity Tests; Minocycline; Phenotype; Tetracyclines

1995

In vitro activities of two glycylcyclines against gram-positive bacteria.

Antimicrobial agents and chemotherapy, 1994, Volume: 38, Issue:3

The glycylcyclines designated CL 329,998 and CL 331,002 are N,N-dimethylglycylamido derivatives of minocycline and 6-demethyl-6-deoxytetracycline, respectively. In vitro activities of these two antimicrobial agents were compared with those of tetracycline, minocycline, and seven other antimicrobial agents against 412 gram-positive organisms. Both new drugs were significantly more active than minocycline against methicillin-resistant Staphylococcus aureus (MICs for 90% of isolates tested, 0.25 and 0.5 microgram/ml versus 4 micrograms/ml). CL 329,998 inhibited all streptococci, lactobacilli, and Leuconostoc spp. at concentrations of < or = 0.5 microgram/ml, with CL 331,002 slightly less active against some species. All enterococci, including minocycline-resistant and multidrug-resistant isolates, were inhibited at < or = 0.5- and < or = 1.0-microgram/ml concentrations of the new drugs, respectively. Only bacteriostatic activity was evident by time-kill curves. The two glycylcyclines demonstrated activities in vitro that were superior to those of minocycline against several gram-positive bacterial species, and at relatively low concentrations, they inhibited isolates resistant to both tetracycline and minocycline.

Topics: Anti-Bacterial Agents; Drug Resistance, Microbial; Gram-Positive Bacteria; Gram-Positive Bacterial Infections; Humans; Microbial Sensitivity Tests; Minocycline; Tetracyclines; Time Factors

1994